MNG Laboratories, a globally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing, is pleased to announce the appointment of Humberto Huerta as Senior Director of Business Development.
ATLANTA, GA, November 01, 2017 /24-7PressRelease/ — MNG Laboratories, a globally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing, is pleased to announce the appointment of Humberto Huerta as Senior Director of Business Development.
Mr. Huerta brings 27 years of experience in the genetic/diagnostic testing field and will lead MNG’s expansion into the global neurogenetic testing field.
“We are pleased to have Humberto join our executive team. He will leverage his success in diagnostics and enable MNG to capitalize on the global opportunity for our products. We have introduced significant new tests to our growing portfolio of next generation sequencing products, including our MNG Exome, MNG Transcriptome and MNG Carrier Exome and we look forward to Humberto’s leadership in expanding the availability of these tests.” – Terry Conrad, MNG President and CEO
Mr. Huerta most recently held a commercial leadership role at Cynvenio Biosystems, and prior to that, held senior level positions at Ambry Genetics, including Senior Director of Global Development. He was an intricate part of building Ambry’s US and international business and successfully lead the firm’s global marketing, commercial operations, and diagnostic development teams. In addition, he has held sales and management positions at Ciba Corning, Beckman Instruments, Therakos, Oncotech, Siemens, and Cepheid.
“MNG has prided itself on providing answers for client’s toughest neurogenetic diagnostic challenges. I look forward to expanding the company’s role as a global leader in neurogenetics.” – Humberto Huerta – MNG Senior Director of Business Development.
MNG Laboratories is an internationally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing. We are committed to a patient-centered testing menu, high-quality diagnostics, and first-in-class reporting driven by our Genome MaNaGer analysis pipeline.
Our Neurogenetic Answers reporting process helps us stay at the forefront of the evolving genetics field. Our team-based approach to data interpretation ensures we provide actionable results on the variants that cause or are likely to cause disease.
As part of MNG’s comprehensive approach to diagnostics they have a team of customer support -specialist and scientific personnel who will answer all your questions regarding our process, technology, and reports.
With over 15 years of neurogenetic experience, and powered by a culture of discovery and advancement, MNG Laboratories delivers results that make a difference for patients and their families.
More information about MNG Laboratories can be found at mnglabs.com.
Terry J. Conrad
For the original version of this press release, please visit 24-7PressRelease.com here